Ep 91: 2026 Diabetes Predictions: Retatrutide, Oral GLP-1s & Stem Cell Breakthroughs… and more!
In this episode you will explore:
- Disease-Modifying Therapies for T1D: Preserving beta cell function after T1D diagnosis and why this represents a major shift in treatment goals.
- New Medications for Type 2 Diabetes: Oral GLP-1s, dual- and triple-agonist therapies, and what they may offer beyond current options.
- GLP-1s in Type 1 Diabetes: Where the research stands, off-label use today, and what future approvals could look like.
- Once-Weekly Basal Insulin: Why it’s promising for type 2 diabetes and who it’s best suited for.
- Inhaled Insulin Updates: New dosing guidance and expanded use cases.
- Continuous Ketone Monitoring: How this technology could improve safety and open doors for additional therapies in T1D.
- Cure-Oriented Research: Stem cell and gene therapy approaches that aim to restore insulin production.
- The Big Picture in 2026: Why 2026 represents real momentum — and what it could mean for access, outcomes, and quality of life.
What new advancements are actually coming in diabetes care in 2026 and what’s in store in the near future? In this episode, Dr. Steve Edelman and Dr. Jeremy Pettus both take a look at the diabetes treatments and technologies they believe are most likely to arrive in 2026.
Together, they walk through emerging therapies for both type 1 and type 2 diabetes, focusing on developments that are no longer theoretical but actively moving through late-stage trials and regulatory review. The conversation covers disease-modifying treatments, next-generation medications, and technology advances that could meaningfully change daily diabetes management.
Leave a Reply